TrialInternational journal of cancer2026

Nonavalent HPV vaccine to prevent recurrent anal or vulvar high-grade squamous intraepithelial lesions (VIVA trial): A randomized, double-blind, placebo-controlled trial.

Helen C Stankiewicz Karita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.